BACKGROUND: A single dose of the histone deacetylase inhibitor vorinostat (VOR) up-regulates HIV RNA expression within resting CD4(+) T cells of treated, aviremic human immunodeficiency virus (HIV)-positive participants. The ability of multiple exposures to VOR to repeatedly disrupt latency has not been directly measured, to our knowledge. METHODS: Five participants in whom resting CD4(+) T-cell-associated HIV RNA (rc-RNA) increased after a single dose of VOR agreed to receive daily VOR Monday through Wednesday for 8 weekly cycles. VOR serum levels, peripheral blood mononuclear cell histone acetylation, plasma HIV RNA single-copy assays, rc-RNA, total cellular HIV DNA, and quantitative viral outgrowth assays from resting CD4(+) T cells were assayed. RESULTS: VOR was well tolerated, with exposures within expected parameters. However, rc-RNA measured after dose 11 (second dose of cycle 4) or dose 22 (second dose of cycle 8) increased significantly in only 3 of the 5 participants, and the magnitude of the rc-RNA increase was much reduced compared with that after a single dose. Changes in histone acetylation were blunted. Results of quantitative viral outgrowth and other assays were unchanged. CONCLUSIONS: Although HIV latency is disrupted by an initial VOR dose, the effect of subsequent doses in this protocol was much reduced. We hypothesize that the global effect of VOR results in a refractory period of ≥ 24 hours. The optimal schedule for VOR administration is still to be defined.
BACKGROUND: A single dose of the histone deacetylase inhibitor vorinostat (VOR) up-regulates HIV RNA expression within resting CD4(+) T cells of treated, aviremic human immunodeficiency virus (HIV)-positive participants. The ability of multiple exposures to VOR to repeatedly disrupt latency has not been directly measured, to our knowledge. METHODS: Five participants in whom resting CD4(+) T-cell-associated HIV RNA (rc-RNA) increased after a single dose of VOR agreed to receive daily VOR Monday through Wednesday for 8 weekly cycles. VOR serum levels, peripheral blood mononuclear cell histone acetylation, plasma HIV RNA single-copy assays, rc-RNA, total cellular HIV DNA, and quantitative viral outgrowth assays from resting CD4(+) T cells were assayed. RESULTS: VOR was well tolerated, with exposures within expected parameters. However, rc-RNA measured after dose 11 (second dose of cycle 4) or dose 22 (second dose of cycle 8) increased significantly in only 3 of the 5 participants, and the magnitude of the rc-RNA increase was much reduced compared with that after a single dose. Changes in histone acetylation were blunted. Results of quantitative viral outgrowth and other assays were unchanged. CONCLUSIONS: Although HIV latency is disrupted by an initial VOR dose, the effect of subsequent doses in this protocol was much reduced. We hypothesize that the global effect of VOR results in a refractory period of ≥ 24 hours. The optimal schedule for VOR administration is still to be defined.
Authors: Eric H Rubin; Nancy G B Agrawal; Evan J Friedman; Pamela Scott; Kathryn E Mazina; Linda Sun; Lihong Du; Justin L Ricker; Stanley R Frankel; Keith M Gottesdiener; John A Wagner; Marian Iwamoto Journal: Clin Cancer Res Date: 2006-12-01 Impact factor: 12.531
Authors: Rochelle P Walensky; A David Paltiel; Elena Losina; Lauren M Mercincavage; Bruce R Schackman; Paul E Sax; Milton C Weinstein; Kenneth A Freedberg Journal: J Infect Dis Date: 2006-06-01 Impact factor: 5.226
Authors: Nancie M Archin; Kara S Keedy; Amy Espeseth; Herbert Dang; Daria J Hazuda; David M Margolis Journal: AIDS Date: 2009-09-10 Impact factor: 4.177
Authors: Kara S Keedy; Nancie M Archin; Adam T Gates; Amy Espeseth; Daria J Hazuda; David M Margolis Journal: J Virol Date: 2009-03-11 Impact factor: 5.103
Authors: Nancy M Archin; Joseph J Eron; Sarah Palmer; Anne Hartmann-Duff; Jeffery A Martinson; Ann Wiegand; Nicholas Bandarenko; John L Schmitz; Ronald J Bosch; Alan L Landay; John M Coffin; David M Margolis Journal: AIDS Date: 2008-06-19 Impact factor: 4.177
Authors: Nancie M Archin; Jennifer L Kirchherr; Julia Am Sung; Genevieve Clutton; Katherine Sholtis; Yinyan Xu; Brigitte Allard; Erin Stuelke; Angela D Kashuba; Joann D Kuruc; Joseph Eron; Cynthia L Gay; Nilu Goonetilleke; David M Margolis Journal: J Clin Invest Date: 2017-07-17 Impact factor: 14.808
Authors: Wen Shi Lee; Jonathan Richard; Marit Lichtfuss; Amos B Smith; Jongwoo Park; Joel R Courter; Bruno N Melillo; Joseph G Sodroski; Daniel E Kaufmann; Andrés Finzi; Matthew S Parsons; Stephen J Kent Journal: J Virol Date: 2015-12-09 Impact factor: 5.103